Related references
Note: Only part of the references are listed.Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial
Meera Gurumurthy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model
Claire M. Naftalin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum
Jean-Philippe Lanoix et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection
Kristian Tonby et al.
BMC INFECTIOUS DISEASES (2016)
Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Robert S. Wallis et al.
LANCET INFECTIOUS DISEASES (2016)
Adjunct Strategies for Tuberculosis vaccines: Modulating Key immune Cell Regulatory Mechanisms to Potentiate vaccination
Lakshmi Jayashankar et al.
FRONTIERS IN IMMUNOLOGY (2016)
Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naive Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial
Daniel F. Hoft et al.
EBIOMEDICINE (2016)
Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults
Kok-Yong Seng et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study
Kim H. Hee et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2015)
Verapamil, and Its Metabolite Norverapamil, Inhibit Macrophage-induced, Bacterial Efflux Pump-mediated Tolerance to Multiple Anti-tubercular Drugs
Kristin N. Adams et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk
Katrin D. Mayer-Barber et al.
NATURE (2014)
Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis
Robert S. Wallis et al.
PLOS ONE (2014)
Ibuprofen Therapy Resulted in Significantly Decreased Tissue Bacillary Loads and Increased Survival in a New Murine Experimental Model of Active Tuberculosis
Cristina Vilaplana et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin-resistant Mycobacterium tuberculosis through Efflux
Gail E. Louw et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Inhibition of Bacterial Multidrug Resistance by Celecoxib, a Cyclooxygenase-2 Inhibitor
Arunasree M. Kalle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis
Robert S. Wallis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Prostaglandins and Inflammation
Emanuela Ricciotti et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins
C. Peres-Buzalaf et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2011)
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line
Karnati R. Roy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects
Jules I. Schwartz et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population
Luis Alberto Garcia Rodriguez et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice
Noton Kumar Dutta et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis
Sean T. Byrne et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
A combination of a transforming growth factor-β antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis
R Hernández-Pando et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo
S von Aulock et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Whole blood bactericidal activity during treatment of pulmonary tuberculosis
RS Wallis et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis
JM Moreno et al.
IMMUNOLOGY (2002)
Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide
Y Zhang et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2002)
A whole blood bactericidal assay for tuberculosis
RS Wallis et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis
LJV Piddock et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Share Paper
